Literature DB >> 21094952

Mental, motor, and language development of toddlers with neurofibromatosis type 1.

Jennifer Lorenzo1, Belinda Barton, Maria T Acosta, Kathryn North.   

Abstract

OBJECTIVE: To examine the mental, motor, and language development of toddlers with neurofibromatosis type 1 (NF1). STUDY
DESIGN: In this cross-sectional study, 39 toddlers with NF1 (aged 21-30 months) and 42 age-matched control children were assessed using the Bayley Scales of Infant Development, Second Edition. Basic vocabulary was assessed with the language subtests from the Wechsler Preschool and Primary Scale of Intelligence, Third Edition. Parents completed questionnaires evaluating the children's expressive language, behavior, and executive functioning. The χ(2) test, independent t test, Mann-Whitney U test, and analysis of covariance were used to examine differences between the two groups.
RESULTS: The toddlers with NF1 had significantly poorer mental and motor development than the control participants. Parental responses indicated that most of the children with NF1 had delayed language skills. No differences in behavior and executive functioning were noted between the two groups of children.
CONCLUSIONS: Children with NF1 as young as age 30 months demonstrate early signs of mental, motor, and language difficulties. Age 2 years may be the appropriate time to perform an initial developmental assessment to identify mental, motor, and language impairments in children with NF1.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21094952     DOI: 10.1016/j.jpeds.2010.10.001

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1.

Authors:  Sandra P Toelle; Andrea Poretti; Peter Weber; Tatjana Seute; Jacoline E C Bromberg; Ianina Scheer; Eugen Boltshauser
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

Review 2.  The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research.

Authors:  Maria T Acosta; Carrie E Bearden; F Xavier Castellanos; Xavier F Castellanos; Laurie Cutting; Ype Elgersma; Gerard Gioia; David H Gutmann; Yong-Seok Lee; Eric Legius; Maximillian Muenke; Kathryn North; Luis F Parada; Nancy Ratner; Kim Hunter-Schaedle; Alcino J Silva
Journal:  Am J Med Genet A       Date:  2012-07-20       Impact factor: 2.802

3.  Longitudinal Investigation of Early Motor Development in Neurofibromatosis Type 1.

Authors:  Sara K Pardej; Danielle M Glad; Christina L Casnar; Kelly M Janke; Bonita P Klein-Tasman
Journal:  J Pediatr Psychol       Date:  2022-02-14

4.  Neurofibromatosis type 1 (NF1) with an unusually severe phenotype due to digeny for NF1 and ryanodine receptor 1 associated myopathy.

Authors:  Florence Martin; Veronika Kana; Andrea Capone Mori; Dirk Fischer; Nicolas Parkin; Eugen Boltshauser; Elisabeth Jane Rushing; Andrea Klein
Journal:  Eur J Pediatr       Date:  2014-04-08       Impact factor: 3.183

5.  Cognitive and psychosocial phenotype of young children with neurofibromatosis-1.

Authors:  Bonita P Klein-Tasman; Kelly M Janke; Wen Luo; Christy L Casnar; Scott J Hunter; James Tonsgard; Pamela Trapane; Faye van der Fluit; Lorri A Kais
Journal:  J Int Neuropsychol Soc       Date:  2013-11-15       Impact factor: 2.892

6.  Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.

Authors:  Michel Kalamarides; Maria T Acosta; Dusica Babovic-Vuksanovic; Olli Carpen; Karen Cichowski; D Gareth Evans; Filippo Giancotti; C Oliver Hanemann; David Ingram; Alison C Lloyd; Debra A Mayes; Ludwine Messiaen; Helen Morrison; Kathryn North; Roger Packer; Duojia Pan; Anat Stemmer-Rachamimov; Meena Upadhyaya; David Viskochil; Margret R Wallace; Kim Hunter-Schaedle; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2011-11-16       Impact factor: 17.088

7.  Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.

Authors:  Edward Kim; Yuan Wang; Sun-Jung Kim; Miriam Bornhorst; Emmanuelle S Jecrois; Todd E Anthony; Chenran Wang; Yi E Li; Jun-Lin Guan; Geoffrey G Murphy; Yuan Zhu
Journal:  Elife       Date:  2014-12-23       Impact factor: 8.140

8.  Motor problems in children with neurofibromatosis type 1.

Authors:  André B Rietman; Rianne Oostenbrink; Sanne Bongers; Eddy Gaukema; Sandra van Abeelen; Jos G Hendriksen; Caspar W N Looman; Pieter F A de Nijs; Marie-Claire de Wit
Journal:  J Neurodev Disord       Date:  2017-05-19       Impact factor: 4.025

9.  Adaptive behavior in young children with neurofibromatosis type 1.

Authors:  Bonita P Klein-Tasman; Alina M Colon; Natalie Brei; Faye van der Fluit; Christina L Casnar; Kelly M Janke; Donald Basel; Dawn H Siegel; Jasmine A Walker
Journal:  Int J Pediatr       Date:  2013-11-19

10.  Early development of infants with neurofibromatosis type 1: a case series.

Authors:  Anna May Kolesnik; Emily Jane Harrison Jones; Shruti Garg; Jonathan Green; Tony Charman; Mark Henry Johnson
Journal:  Mol Autism       Date:  2017-11-23       Impact factor: 7.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.